Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTEMTO 2: Tiotropium + Olodaterol FDC in COPD
NCT02006732Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of olodaterol in chronic obstructive pulmonary disease (COPD), sponsored by Boehringer Ingelheim. Started Nov 2013; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02006732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02006732.